-
Quintiles Poised To Benefit From Pharmaceutical R&D Outsourcing
Thursday, August 18, 2016 - 11:48am | 310Argus maintains its Buy rating on Quintiles Transnational Holdings Inc (NYSE: Q) shares. The brokerage also lifted its price target from $75 to $85. The move comes after the company delivered better-than-estimated second-quarter results and an increased outlook on July 27. Analysts Jacob Kilstein...
-
AbbVie Shares Trading At A Discount To Other Pharmaceuticals; Argus Reaffirms With A Buy Rating
Monday, August 8, 2016 - 1:23pm | 314David Toung and Casey Meyers, analysts at Argus Research, reaffirmed a Buy rating on AbbVie Inc (NYSE: ABBV) on Monday with an $85 price target following the company's "strong" second quarter earnings print. The analysts noted that not only were AbbVie's results driven by sales of Humira and...
-
Raytheon's Focus On International, Cybersecurity Could Generate Strong Growth
Wednesday, August 3, 2016 - 1:43pm | 381Argus has raised its 2016 EPS estimate and price target on the shares of Raytheon Company (NYSE: RTN), saying the company's focus on its international and cybersecurity businesses could generate stronger growth over the next three to five years. Argus, which maintains its Buy rating on the stock,...
-
Sun Life Financial Still Seeing Strong Results Despite Low Interest Rates
Friday, June 17, 2016 - 2:37pm | 303Argus analysts Jacob Kilstein and Casey Meyers have boosted the price target of Sun Life Financial Inc (NYSE: SLF) shares to $37.00 from $35.00. The analysts retained their rating of Buy on the stock. The brokerage thinks that its revised target implies a multiple of 12.8X to its 2016 EPS estimate...